Innsbruck

• HR-NBL2: High-risk neuroblastoma study 2.0 of SIOP-Europe- Neuroblastoma/SIOPEN: Randomised, international and multicentric phase 3 study t … Recruiting
  2024-514917-36-00 5 2024-11-21 Patients with High Risk Neuroblastoma
• A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-fibrosis) Recruiting
  2023-509912-27-00 5 2024-11-07 Metabolic Dysfunction-Associated Steatotic Liver Disease(MASH) / Nonal
• Adding Navtemadlin to Ruxolitinib for Patients with Myelofibrosis Recruiting
  2023-504724-25-00 5 2024-10-16 Primary Myelofibrosis
• Comparison of local anaesthesia and regional anaesthesia (PECS II block) on QoR-15 in patients undergoing subpectoral implantation of cardia … Recruiting
  2023-508997-27-00 6 2024-10-14 Need for a subpectoral implantation of cardiac implantable electronic
• Clinical trial comparing MK-2870 given with pembrolizumab to pembrolizumab alone in participants who have had surgery for NSCLC Recruiting
  2023-508012-35-00 5 2024-10-02 Newly diagnosed NSCLC with resectable clinical Stage II, IIIA or IIIB
• The One-Month DAPT with Ticagrelor In CABG PatieNts Trial (ODIN) Recruiting
  2023-506613-22-00 5 2024-09-25 coronary artery disease
• Evaluating the Diagnostic Performance of Human Epidermal Growth Factor Receptor 2 (HER2) targeted Positron Emission Tomography and Computed … Recruiting
  2024-511419-22-00 10 2024-09-03 Hormone receptor positive/HER2 negative, triple-negative or HER2 posit
• A randomised, controlled trial to investigate the effect of a six-week intensified pharmacological treatment for major depressive disorder c … Recruiting
  2023-506617-21-00 5 2024-08-29 Major depressive disorder
• Trial to assess the safety and efficacy of high dose pulse intravenous corticosteroid therapy to treat patients with complicated/fulminant a … Recruiting
  2023-504169-22-02 5 2024-07-31 Severe cardiac inflammation
• A study comparing TAR-210 versus single agent treatment instilled directly into the bladder in people with bladder cancer with FGFR gene alt … Recruiting
  2023-507684-19-00 5 2024-07-24 FGFR+ Intermediate-risk Non-muscle Invasive Bladder Cancer
• A randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein(a) lowering with pelacarsen (TQJ230) on … Recruiting
  2022-502135-19-00 4 2024-07-18 Calcific Aortic Valve Stenosis
• Clinical trial of MK-2870 in combination with pembrolizumab in people who have had surgery to treat triple negative breast cancer Recruiting
  2023-504962-52-00 5 2024-07-10 Triple negative breast cancer.
• N-PLUS Recruiting
  2022-502559-69-01 4 2024-07-04 advanced (FIGO stage IIIA, IIIB, IIIC, or IV of the 2014 FIGO classifi
• HYDROchlorothiazide to PROTECT polycystic kidney disease patients and improve their quality of life (HYDRO-PROTECT) Recruiting
  2022-500210-26-00 5 2024-06-28 Autosomal Dominant Polycystic Kidney Disease (ADPKD)
• A Phase 2 Study to Evaluate MORF-057 in Adults with Moderately to Severely Active Crohn’s Disease Recruiting
  2023-508158-24-00 4 2024-06-25 Moderately to Severely Active Crohn’s Disease
• A study to discover if ZED1227 can improve continued celiac disease symptoms despite a gluten-free diet Recruiting
  2023-506150-21-00 4 2024-05-29 Celiac Disease
• A study to investigate long-term safety and tolerability of tolebrutinib in participants with multiple sclerosis Recruiting
  2023-503631-18-01 5 2024-05-20 Nervous system diseases
• Study of GS-5290 in Participants With Moderately to Severely Active Ulcerative Colitis Recruiting
  2022-501119-14-01 4 2024-04-16 Ulcerative Colitis
• An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) Recruiting
  2023-504031-41-00 5 2024-03-25 ER+/HER2- Early Breast Cancer
• A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease (PASADENA) Recruiting
  2023-504472-24-00 4 2024-03-19 Early Idiopathic Parkinson’s disease (PD)
• ​​Lomustine with or without a second round of brain radiation for the reappearance of glioblastoma Recruiting
  2023-505267-36-00 5 2024-03-15 Glioblastoma
• An Open-label Study of XEN1101 in Epilepsy Recruiting
  2022-502282-24-00 5 2024-02-14 Primary generalized tonic-clonic seizures
• Frexalimab in preservation of endogenous insulin secretion compared to placebo in adults, adolescents and children on top of Insulin therapy … Recruiting
  2022-500531-36-00 4 2024-02-02 Type 1 diabetes mellitus
• A Trial to Learn if Odronextamab Combined with Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined … Recruiting
  2022-502113-28-00 5 2024-02-01 Follicular lymphoma

Showing 121–144 of 347 trials